| Description | Varespladib methyl (LY333013), a bioavailable prodrug of Varespladib, is a selective group II secretory phospholipase A2 inhibitor. |
| In vitro | Varespladib methyl 在纳摩尔和皮摩尔浓度下，对来自六大洲的28种医学上重要的蛇毒展示出高水平的分泌型PLA2抑制作用[1]。 |
| Synonyms | A-002, LY333013 |
| molecular weight | 394.42 |
| Molecular formula | C22H22N2O5 |
| CAS | 172733-08-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 95 mg/mL (240.58 mM), Sonication is recommended. |
| References | 1. Lewin M, et al. Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation. Toxins (Basel). 2016 Aug 25;8(9). pii: E248. 2. Bradley JD, et al. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J Rheumatol. 2005 Mar;32(3):417-23. |